The aim of the Oncology Committee of the French Urology Association is to propose updated recommendations for the diagnosis and management of localized prostate cancer (PCa).
A systematic review of the literature from 2022 to 2024 was conducted by the CCAFU on the elements of diagnosis and therapeutic management of localized PCa, evaluating references with their level of evidence.
The recommendations set out the genetics, epidemiology and diagnostic methods of PCa, as well as the concepts of screening and early detection. MRI, the reference imaging test for localized cancer, is recommended before prostate biopsies are performed. Molecular imaging is an option for disease staging. Performing biopsies via the transperineal route reduces the risk of infection. Active surveillance is the standard treatment for tumours with a low risk of progression. Therapeutic methods are described in detail, and recommended according to the clinical situation.
This update of French recommendations should help to improve the management of localized PCa.
The French journal of urology. 2024 Nov [Epub]
Guillaume Ploussard, Michaël Baboudjian, Eric Barret, Laurent Brureau, Gaëlle Fiard, Gaëlle Fromont, Jonathan Olivier, Charles Dariane, Romain Mathieu, François Rozet, Arthur Peyrottes, Guilhem Roubaud, Raphaële Renard-Penna, Paul Sargos, Stéphane Supiot, Léa Turpin, Morgan Rouprêt, Comité de Cancérologie de l’Association Française d’Urologie, Groupe Prostate, Maison de l’Urologie
Department of Urology, La Croix du Sud Hospital, Quint-Fonsegrives, France; Department of Radiotherapy, Institut Curie, Paris, France. Electronic address: ., Department of Urology, AP-HM Marseille, Marseille, France., Department of Urology, Institut Mutualiste Montsouris, Paris, France., Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (Irset), UMR_S 1085, 97110 Pointe-à-Pitre, Guadeloupe., Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France., Department of Pathology, CHRU, 37000 Tours, France., Department of Urology, CHRU de Lille, Lille, France., Department of Urology, Hôpital européen Georges-Pompidou, AP-HP, Paris, France; Paris University, U1151 Inserm, INEM, Necker, Paris, France., Department of Urology, CHU de Rennes, Rennes, France., Department of Urology, CHU Saint-Louis, Paris, France., Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France., Sorbonne University, AP-HP, Radiology, Pitié-Salpêtrière Hospital, 75013 Paris, France., Department of Radiotherapy, Institut Bergonié, 33000 Bordeaux, France., Radiotherapy Department, Institut de Cancérologie de l'Ouest, Saint-Herblain, France., Nuclear Medicine Department, Hôpital Foch, Suresnes, France., Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitié-Salpêtrière Hospital, 75013 Paris, France., 11, rue Viète, 75017 Paris, France.